ClinicalTrials.gg
CompletedNCT00518531Updated Dec 3, 2019Results posted

Denosumab Adherence Preference Satisfaction Study

A Phase 3 interventional study of alendronate and denosumab in Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2019-12-03.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
55 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.

Enrollment
7th of 51
250 · median 60
Started
2007
with 2 others
Phase 3
12 of 51
none open now
Registered
24th of 51
by date
Lead sponsor
1 of 51
Amgen

Among the 51 studies testing alendronate in Osteoporosis, this one is the 7th largest by enrollment, is one of 3 that started in 2007, is one of 12 in phase 3, and was the 24th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About alendronate

Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 55 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing alendronate in Osteoporosis, or all of them as a file.
02

Study summary

The primary objective is to evaluate the adherence of subjects to subcutaneous (SC) 60 mg denosumab every 6 months (Q6M) treatment compared to oral 70 mg alendronate once a week (QW) treatment at the end of treatment period 1 (12 months).

03

Conditions studied

  • Osteoporosis

Keywords

  • osteoporosis
  • low bone mineral density
  • alendronate
  • denosumab
  • adherence
  • preference
  • satisfaction
  • postmenopausal
  • women
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory women based on medical history
  • > or = 55 years of age at the start of screening
  • Screening bone mineral density (BMD) values (g/cm²), at the lumbar spine OR femoral neck OR total hip that occur within the specified ranges based on the particular scanner that is used. At least 2 lumbar vertebrae must be evaluable by Dual X-ray Absorptiometry (DXA), or at least one hip must be evaluable by DXA
  • Provide written before any study specific procedure is performed.

Exclusion criteria

Exclusion Criteria:

  • Any disorder that compromises the ability of the subject to give written and/or to comply with study procedures
  • Hyper- or hypothyroidism; however, stable subjects, in the investigator's opinion, on thyroid hormone replacement therapy are allowed
  • Current hyper- or hypoparathyroidism
  • Current hypo- or hyper calcemia based on the central laboratory reference ranges for albumin-adjusted serum calcium
  • Rheumatoid arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or cirrhosis of the liver
  • Any metabolic bone disease, e.g. osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings
  • Any symptomatic vertebral fracture within 3 months prior to screening
  • Previous participation in clinical trials with denosumab
  • Vitamin D deficiency [25(OH) vitamin D level \< 20 ng/mL (\<49.9 nmol/L)]
  • to alendronate therapy; contraindications for alendronate therapy include:

    1. Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia.
    2. Inability to stand or sit upright for at least 30 minutes.
    3. to alendronate (ALN) or other constituents of ALN tablets.
  • Any known prior bisphosphonate use
  • Currently enrolled in or has not yet completed at least 1 month since ending other device or drug trail (s), or subject is receiving other investigational agent(s).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
250 participants (actual)

Study arms

  • Other
    Treatment Sequence B

    When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).

    Drug: alendronate · Drug: denosumab

  • Other
    Treatment Sequence A

    When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).

    Drug: alendronate · Drug: denosumab

Interventions

  • Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.

  • Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.

06

What researchers measure

Primary outcomes

  1. Adherence With Treatment in the First Treatment Period

    A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed non-adherent to treatment.

    Time frame: Treatment period 1 (Month 1 to Month 12)

Secondary outcomes

  1. Adherence With Treatment in the Second Treatment Period

    A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed nonadherent to treatment.

    Time frame: Treatment period 2 (Months 13 to 24)

  2. Compliance With Treatment in the First Treatment Period

    Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance).

    Time frame: Treatment period 1 (Month 1 to Month 12)

  3. Compliance With Treatment in the Second Treatment Period

    Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance).

    Time frame: Treatment period 2 (Month 13 to Month 24)

  4. Persistence With Treatment in the First Treatment Period

    Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period.

    Time frame: Treatment period 1 (Month 1 to Month 12)

  5. Persistence With Treatment in the Second Treatment Period

    Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period.

    Time frame: Treatment period 2 (Month 13 to Month 24)

  6. Time to Non-adherence to Alendronate Treatment in the First Treatment Period

    Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit.

    Time frame: Treatment Period 1 (Month 1 to Month 12)

  7. Time to Non-adherence to Alendronate Treatment in the Second Treatment Period

    Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit.

    Time frame: Treatment Period 2 (Month 13 to Month 24)

  8. Time to Non-compliance to Alendronate Treatment in the First Treatment Period

    Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period.

    Time frame: Treatment period 1 (Month 1 to Month 12)

  9. Time to Non-compliance to Alendronate Treatment in the Second Treatment Period

    Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period.

    Time frame: Treatment period 2 (Month 13 to Month 24)

  10. Time to Non-persistence to Alendronate Treatment in the First Treatment Period

    Time to non-persistence for alendronate is defined for each treatment period as the first time \<2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System.

    Time frame: Treatment period 1 (Month 1 to Month 12)

  11. Time to Non-persistence to Alendronate Treatment in the Second Treatment Period

    Time to non-persistence for alendronate is defined for each treatment period as the first time \<2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System.

    Time frame: Treatment period 2 (Month 13 to Month 24)

  12. Overall Satisfaction to Study Treatment

    Participant satisfaction with their treatment was assessed using question 7 (ie, "Please rate your satisfaction with the weekly pill on the following: frequency of administration; mode of administration \[taking a pill\]; convenience; overall satisfaction") and question 8 (ie, "Please rate your satisfaction with the six month injection on the following: frequency of administration; mode of administration \[receiving an injection\]; convenience; overall satisfaction") from the Preference Satisfaction Questionnaire (PSQ) at the end of each treatment period. The PSQ is a 34 item, self-report questionnaire of participants' preference and satisfaction for each of the two study treatments. Possible answers include: "Not at all Satisfied", "A Little Satisfied", "Moderately Satisfied", "Quite Satisfied", and "Very Satisfied".

    Time frame: End of treatment period 1 (Month 12)

  13. Beliefs About Medicines Questionnaire (BMQ): Necessity Score

    The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' beliefs about the necessity of the prescribed medication to treat osteoporosis were based on the average of 5 items from the BMQ that form the necessity score. The necessity score ranges from 1 to 5, with higher scores indicating stronger beliefs about the necessity of the prescribed medication for controlling osteoporosis.

    Time frame: Baseline, Month 6, Month 12, Month 18 and Month 24

  14. Beliefs About Medicines Questionnaire (BMQ) Concern Score

    The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' concern about the adverse consequences of taking the medication for controlling osteoporosis was based on the average of 10 items from the BMQ that form the concern score. The concern score ranges from 1 to 5, with higher scores indicating stronger concerns about the adverse consequences of taking the prescribed medication for controlling osteoporosis.

    Time frame: Baseline and Month 6, Month 12, Month 18, and Month 24

  15. Beliefs About Medicines Questionnaire (BMQ) Preference Score

    The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. The BMQ preference score, which measures a participant's overall evaluation of a medication, is based on the average of 7 items in the BMQ. The preference score ranges from 1 to 5, with higher scores indicating stronger preference for one medication over the other.

    Time frame: Baseline and Month 6, Month 12, Month 18, and Month 24

  16. Medication Adherence Rating Scale (MARS) to Alendronate in the First Treatment Period

    The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period.

    Time frame: Month 6, Month 12 (treatment period 1)

  17. Medication Adherence Rating Scale (MARS) to Alendronate in the Second Treatment Period

    The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period.

    Time frame: Month 18, Month 24 (treatment period 2)

07

Results

Posted Jan 7, 2014

Participant flow

First subject enrolled 03-Oct-07, last subject enrolled 25-Jun-08; First subject crossovered 22-May-08, last subject crossovered 25-Jun-09;

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneAlendronate in Period 1 Then Denosumab in Period 2Denosumab in Period 1 Then Alendronate in Period 2
Started124126
Received treatment119124
Completed106114
Not completed1812
Withdrew: Adverse event50
Withdrew: Lost to follow-up53
Withdrew: Physician decision10
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject46
Withdrew: Early crossover13
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneAlendronate in Period 1 Then Denosumab in Period 2Denosumab in Period 1 Then Alendronate in Period 2
Started106115
Received treatment106110
Completed10395
Not completed320
Withdrew: Withdrawal by subject08
Withdrew: Complete out of scheduled visit window12
Withdrew: Adverse event17
Withdrew: Protocol-specified criteria01
Withdrew: Non-compliance12

Outcome measures

PrimaryAdherence With Treatment in the First Treatment Period

A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed non-adherent to treatment.

Time frame:
Treatment period 1 (Month 1 to Month 12)
Reported as:
Number · Participants
Adherence With Treatment in the First Treatment Period
ParticipantsAlendronateDenosumab
Yes95111
No2915
Statistical analysis
  • Alendronate vs Denosumab · Cochran-Mantel-Haenszel · p = 0.0259 (All statistical hypothesis tests were conducted at the 0.05 significance level. No adjustment was employed for multiple comparisons.) · Risk difference (rd): 10.5 · 95% CI 1.3 to 19.7Positive values for absolute risk reduction favor denosumab.
SecondaryAdherence With Treatment in the Second Treatment Period

A participant was considered adherent to denosumab treatment if the participant: - received 2 denosumab injections (overall treatment compliance); - took each injection 6 months (± 4 weeks) apart (treatment compliance over time); - completed the relevant treatment period (treatment persistence). A participant was considered adherent to alendronate treatment if the participant: - took ≥ 80% QW tablets (overall treatment compliance); - took at least 2 tablets in the last month and completed the relevant treatment period (treatment persistence). Participants who did not meet all criteria for their assigned treatment were deemed nonadherent to treatment.

Time frame:
Treatment period 2 (Months 13 to 24)
Reported as:
Number · Participants
Adherence With Treatment in the Second Treatment Period
ParticipantsAlendronateDenosumab
Yes7398
No428
Statistical analysis
  • Alendronate vs Denosumab · Cochran-Mantel-Haenszel · p = <0.0001 (All statistical hypothesis tests were conducted at the 0.05 significance level. No adjustment was employed for multiple comparisons.) · Risk difference (rd): 30.9 · 95% CI 20.6 to 41.3Positive values for absolute risk reduction favor denosumab.
SecondaryCompliance With Treatment in the First Treatment Period

Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance).

Time frame:
Treatment period 1 (Month 1 to Month 12)
Reported as:
Number · Participants
Compliance With Treatment in the First Treatment Period
ParticipantsAlendronateDenosumab
Yes97114
No2712
Statistical analysis
  • Alendronate vs Denosumab · Cochran-Mantel-Haenszel · p = 0.0138 · Risk difference (rd): 11.00 · 95% CI 2.2 to 19.7Positive values for absolute risk reduction favor denosumab.
SecondaryCompliance With Treatment in the Second Treatment Period

Participants were considered compliant to denosumab treatment if they received 2 denosumab injections (overall treatment compliance) and if they took each injection 6 months (± 4 weeks) apart (treatment compliance over time). Participants were considered compliant to alendronate treatment if they took ≥ 80% QW tablets (overall treatment compliance).

Time frame:
Treatment period 2 (Month 13 to Month 24)
Reported as:
Number · Participants
Compliance With Treatment in the Second Treatment Period
ParticipantsAlendronateDenosumab
Yes7899
No377
Statistical analysis
  • Alendronate vs Denosumab · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 27.7 · 95% CI 17.6 to 37.7Positive values for absolute risk reduction favor denosumab.
SecondaryPersistence With Treatment in the First Treatment Period

Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period.

Time frame:
Treatment period 1 (Month 1 to Month 12)
Reported as:
Number · Participants
Persistence With Treatment in the First Treatment Period
ParticipantsAlendronateDenosumab
Yes99114
No2512
Statistical analysis
  • Alendronate vs Denosumab · Cochran-Mantel-Haenszel · p = 0.0291 · Risk difference (rd): 9.8 · 95% CI 1.1 to 18.5Positive values for absolute risk reduction favor denosumab.
SecondaryPersistence With Treatment in the Second Treatment Period

Denosumab-treated participants were considered persistent to treatment if they completed the relevant treatment period and alendronate-treated participants were considered persistent to treatment if they completed the relevant treatment period and took at least 2 tablets in the last month of the treatment period.

Time frame:
Treatment period 2 (Month 13 to Month 24)
Reported as:
Number · Participants
Persistence With Treatment in the Second Treatment Period
ParticipantsAlendronateDenosumab
Yes82103
No333
Statistical analysis
  • Alendronate vs Denosumab · Cochran-Mantel-Haenszel · p = <0.0001 · Risk difference (rd): 27.4 · 95% CI 18.1 to 36.7Positive values for absolute risk reduction favor denosumab.
SecondaryTime to Non-adherence to Alendronate Treatment in the First Treatment Period

Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit.

Time frame:
Treatment Period 1 (Month 1 to Month 12)
Reported as:
Mean · weeks
Time to Non-adherence to Alendronate Treatment in the First Treatment Period
weeksAlendronate
Time to Non-adherence to Alendronate Treatment in the First Treatment Period43.29 ± 1.46
SecondaryTime to Non-adherence to Alendronate Treatment in the Second Treatment Period

Time to treatment non-adherence for alendronate is defined for each treatment period as the time to treatment non-compliance or time to treatment non-persistence, whichever occurs earliest, for participants with uncensored values. Participants who had both censored time to non-compliance and censored time to non-persistence values were censored in the analysis at the end of treatment period visit.

Time frame:
Treatment Period 2 (Month 13 to Month 24)
Reported as:
Mean · weeks
Time to Non-adherence to Alendronate Treatment in the Second Treatment Period
weeksAlendronate
Time to Non-adherence to Alendronate Treatment in the Second Treatment Period39.45 ± 1.89
SecondaryTime to Non-compliance to Alendronate Treatment in the First Treatment Period

Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period.

Time frame:
Treatment period 1 (Month 1 to Month 12)
Reported as:
Mean · weeks
Time to Non-compliance to Alendronate Treatment in the First Treatment Period
weeksAlendronate
Time to Non-compliance to Alendronate Treatment in the First Treatment Period43.75 ± 1.42
SecondaryTime to Non-compliance to Alendronate Treatment in the Second Treatment Period

Time to treatment non-compliance for alendronate is based on the percent of QW tablets taken and is defined for each treatment period as the first week since Study Day 1 of the treatment period to the week where the percent of QW tablets taken falls below the threshold of ≥ 80% and where the participant can not reach this threshold again during the treatment period.

Time frame:
Treatment period 2 (Month 13 to Month 24)
Reported as:
Mean · weeks
Time to Non-compliance to Alendronate Treatment in the Second Treatment Period
weeksAlendronate
Time to Non-compliance to Alendronate Treatment in the Second Treatment Period39.97 ± 1.87
SecondaryTime to Non-persistence to Alendronate Treatment in the First Treatment Period

Time to non-persistence for alendronate is defined for each treatment period as the first time \<2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System.

Time frame:
Treatment period 1 (Month 1 to Month 12)
Reported as:
Mean · weeks
Time to Non-persistence to Alendronate Treatment in the First Treatment Period
weeksAlendronate
Time to Non-persistence to Alendronate Treatment in the First Treatment Period44.59 ± 1.35
SecondaryTime to Non-persistence to Alendronate Treatment in the Second Treatment Period

Time to non-persistence for alendronate is defined for each treatment period as the first time \<2 tablets were taken in a rolling 4-week time period (e.g. study weeks 1-4, 2-5, 3-6 etc) and where the participant never reaches this threshold again during the treatment period. Tablet intake was tracked using a Medication Event Monitoring System.

Time frame:
Treatment period 2 (Month 13 to Month 24)
Reported as:
Mean · weeks
Time to Non-persistence to Alendronate Treatment in the Second Treatment Period
weeksAlendronate
Time to Non-persistence to Alendronate Treatment in the Second Treatment Period42.76 ± 1.69
SecondaryOverall Satisfaction to Study Treatment

Participant satisfaction with their treatment was assessed using question 7 (ie, "Please rate your satisfaction with the weekly pill on the following: frequency of administration; mode of administration \[taking a pill\]; convenience; overall satisfaction") and question 8 (ie, "Please rate your satisfaction with the six month injection on the following: frequency of administration; mode of administration \[receiving an injection\]; convenience; overall satisfaction") from the Preference Satisfaction Questionnaire (PSQ) at the end of each treatment period. The PSQ is a 34 item, self-report questionnaire of participants' preference and satisfaction for each of the two study treatments. Possible answers include: "Not at all Satisfied", "A Little Satisfied", "Moderately Satisfied", "Quite Satisfied", and "Very Satisfied".

Time frame:
End of treatment period 1 (Month 12)
Reported as:
Number · Participants
Overall Satisfaction to Study Treatment
ParticipantsAlendronateDenosumab
Not at all satisfied33
A little satisfied13
Moderately satisfied172
Quite satisfied3418
Very satisfied5995
SecondaryBeliefs About Medicines Questionnaire (BMQ): Necessity Score

The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' beliefs about the necessity of the prescribed medication to treat osteoporosis were based on the average of 5 items from the BMQ that form the necessity score. The necessity score ranges from 1 to 5, with higher scores indicating stronger beliefs about the necessity of the prescribed medication for controlling osteoporosis.

Time frame:
Baseline, Month 6, Month 12, Month 18 and Month 24
Reported as:
Mean · scores on a scale
Beliefs About Medicines Questionnaire (BMQ): Necessity Score
scores on a scaleAlendronateDenosumab
Baseline (n=104, 117)3.32 ± 0.523.26 ± 0.48
Month 6 (n=106, 114)3.14 ± 0.533.31 ± 0.60
Month 12 (n=103, 95)3.21 ± 0.513.17 ± 0.52
Month 18 (n=98, 98)3.20 ± 0.533.28 ± 0.55
Month 24 (n=91, 100)3.21 ± 0.623.22 ± 0.58
SecondaryBeliefs About Medicines Questionnaire (BMQ) Concern Score

The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. Participants' concern about the adverse consequences of taking the medication for controlling osteoporosis was based on the average of 10 items from the BMQ that form the concern score. The concern score ranges from 1 to 5, with higher scores indicating stronger concerns about the adverse consequences of taking the prescribed medication for controlling osteoporosis.

Time frame:
Baseline and Month 6, Month 12, Month 18, and Month 24
Reported as:
Mean · scores on a scale
Beliefs About Medicines Questionnaire (BMQ) Concern Score
scores on a scaleAlendronateDenosumab
Baseline (n=104, 117)2.33 ± 0.482.43 ± 0.46
Month 6 (n=106, 114)2.22 ± 0.512.12 ± 0.51
Month 12 (n=103, 95)2.57 ± 0.482.51 ± 0.50
Month 18 (n=98, 98)2.43 ± 0.582.24 ± 0.49
Month 24 (n=91, 100)2.39 ± 0.582.18 ± 0.51
SecondaryBeliefs About Medicines Questionnaire (BMQ) Preference Score

The BMQ is a 22- item self-reported questionnaire specific to osteoporosis that measures beliefs about the weekly pill or every 6 months injection. The BMQ consists of 3 subscales measuring beliefs about the necessity of the medication for controlling osteoporosis, concern with the adverse consequences of taking the medication, and preference for one medication over the other. The BMQ preference score, which measures a participant's overall evaluation of a medication, is based on the average of 7 items in the BMQ. The preference score ranges from 1 to 5, with higher scores indicating stronger preference for one medication over the other.

Time frame:
Baseline and Month 6, Month 12, Month 18, and Month 24
Reported as:
Mean · scores on a scale
Beliefs About Medicines Questionnaire (BMQ) Preference Score
scores on a scaleAlendronateDenosumab
Baseline (n=104, 117)2.97 ± 0.403.47 ± 0.43
Month 6 (n=106, 114)3.01 ± 0.533.72 ± 0.47
Month 12 (n=103, 95)2.62 ± 0.503.43 ± 0.45
Month 18 (n=98, 98)2.55 ± 0.563.77 ± 0.47
Month 24 (n=91, 100)2.57 ± 0.653.80 ± 0.52
SecondaryMedication Adherence Rating Scale (MARS) to Alendronate in the First Treatment Period

The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period.

Time frame:
Month 6, Month 12 (treatment period 1)
Reported as:
Mean · scores on a scale
Medication Adherence Rating Scale (MARS) to Alendronate in the First Treatment Period
scores on a scaleAlendronate
Month 6 (n=109)24.3 ± 1.1
Month 12 (n= 100)24.4 ± 1.4
SecondaryMedication Adherence Rating Scale (MARS) to Alendronate in the Second Treatment Period

The MARs questionnaire is a validated, self-reported instrument for assessing treatment adherence. Participants report how often they engage in each of 5 aspects of non-adherent behavior (forgetting to take a dose, changing the dose, stop taking them for a while, deciding to not take a dose, or taking less than instructed). Scores are summed over the 5 items, the total score ranges from 5 to 25 with higher scores indicating greater self-reported adherence. The MARS was collected at the month 6 and month 12 visits of each treatment period only for those participants receiving oral alendronate during that period.

Time frame:
Month 18, Month 24 (treatment period 2)
Reported as:
Mean · scores on a scale
Medication Adherence Rating Scale (MARS) to Alendronate in the Second Treatment Period
scores on a scaleAlendronate
Treatment period 2 Month 6 (n=98)23.4 ± 2.0
Treatment period 2 Month 12 (n= 90)23.8 ± 1.4

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period 1: Alendronate—5/118 (4.2%)24/118 (20.3%)
Treatment Period 1: Denosumab—4/125 (3.2%)31/125 (24.8%)
Treatment Period 2: Alendronate—4/110 (3.6%)21/110 (19.1%)
Treatment Period 2: Denosumab—4/106 (3.8%)13/106 (12.3%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventTreatment Period 1: AlendronateTreatment Period 1: DenosumabTreatment Period 2: AlendronateTreatment Period 2: Denosumab
OsteoarthritisMusculoskeletal and connective tissue disorders0/1182/1250/1101/106
Pelvic massGeneral disorders0/1180/1250/1101/106
Pubis fractureInjury, poisoning and procedural complications0/1180/1250/1101/106
Ovarian neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1180/1250/1101/106
Cerebrovascular accidentNervous system disorders0/1180/1250/1101/106
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1180/1250/1101/106
Hernia painGeneral disorders0/1180/1251/1100/106
Fracture nonunionMusculoskeletal and connective tissue disorders0/1180/1251/1100/106
Joint contractureMusculoskeletal and connective tissue disorders0/1180/1251/1100/106
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1180/1251/1100/106
Most frequent other events
Most frequent other events
EventTreatment Period 1: AlendronateTreatment Period 1: DenosumabTreatment Period 2: AlendronateTreatment Period 2: Denosumab
ArthralgiaMusculoskeletal and connective tissue disorders8/11811/1257/1103/106
Back painMusculoskeletal and connective tissue disorders10/1185/1253/1104/106
Pain in extremityMusculoskeletal and connective tissue disorders5/1189/1254/1105/106
HeadacheNervous system disorders7/1184/1253/1103/106
CoughRespiratory, thoracic and mediastinal disorders6/1185/1255/1101/106

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Alendronate in Period 1 Then Denosumab in Period 2Denosumab in Period 1 Then Alendronate in Period 2Total
Mean65.3 ± 7.765.1 ± 7.665.2 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Alendronate in Period 1 Then Denosumab in Period 2Denosumab in Period 1 Then Alendronate in Period 2Total
Female124126250
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alendronate in Period 1 Then Denosumab in Period 2Denosumab in Period 1 Then Alendronate in Period 2Total
White or Caucasian119115234
Black or African American224
Hispanic or Latino167
Asian134
Japanese101
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL; DAPS Investigators. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012 Jan;23(1):317-26. doi: 10.1007/s00198-011-1780-1. Epub 2011 Sep 17. PubMed 21927922 ↗
  • Kendler DL, Macarios D, Lillestol MJ, Moffett A, Satram-Hoang S, Huang J, Kaur P, Tang ET, Wagman RB, Horne R. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause. 2014 Jan;21(1):25-32. doi: 10.1097/GME.0b013e31828f5e5d. PubMed 23676636 ↗
  • Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, Satram-Hoang S, Yang YC, Kaur P, Macarios D, Siddhanti S; DAPS Investigators. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011 Jun;22(6):1725-35. doi: 10.1007/s00198-010-1378-z. Epub 2010 Sep 9. PubMed 20827547 ↗
  • Kendler D, Chines A, Clark P, Ebeling PR, McClung M, Rhee Y, Huang S, Stad RK. Bone Mineral Density After Transitioning From Denosumab to Alendronate. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e255-64. doi: 10.1210/clinem/dgz095. PubMed 31665314 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2007 to primary completion in Jun 2009, 21 months.

Results were first posted in Jan 2014, 4 years 7 months after primary completion.

Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 21 months is below that.

Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2007
First posted
Aug 20, 2007
StartActual
Sep 1, 2007
Primary completionActual
Jun 1, 2009
CompletionActual
Jun 1, 2010
Results first posted
Jan 7, 2014
Last update
Dec 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00518531
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 20, 2007
Start date
Sep 1, 2007
Primary completion
Jun 1, 2009
Completion
Jun 1, 2010
Results posted
Jan 7, 2014
Last update
Dec 3, 2019

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alendronate · Denosumab

Start the discussion